Developing a vaccine for broad protection against influenza A viruses
Engineering Protein Antigens and their Presentation from Multivalent Scaffolds
This study is working on a new flu vaccine that aims to protect you from different types of flu viruses, including those that have caused pandemics in the past, by boosting your immune response in a stronger and longer-lasting way.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia Institute of Technology NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10884157 on NIH RePORTER |
What this research studies
This research aims to create a vaccine that offers extensive protection against various strains of influenza A viruses, including those responsible for past pandemics. The approach focuses on eliciting a strong and lasting immune response by targeting a specific part of the virus called the stalk domain of hemagglutinin (HA). By using innovative techniques to shield the variable parts of the virus and enhance the immune response, the researchers hope to provide better protection against seasonal and pandemic influenza. This work is crucial as current vaccines often fail to protect against emerging strains due to their narrow focus.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at risk of influenza infection, such as those with compromised immune systems, healthcare workers, and the elderly.
Not a fit: Patients who are not at risk for influenza or those who have already been vaccinated with existing vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that protects against multiple strains of influenza A, potentially reducing the impact of seasonal flu and preventing future pandemics.
How similar studies have performed: Previous research has shown promise in developing broadly neutralizing antibodies against influenza, indicating that this approach could be viable.
Where this research is happening
Atlanta, United States
- Georgia Institute of Technology — Atlanta, United States (Active)
Researchers
- Principal investigator: Kane, Ravi S. — Georgia Institute of Technology
- Study coordinator: Kane, Ravi S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.